Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Davide Ghinolfi et al.|The Lancet Oncology|2023Cited by 184
Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapiesVelia Chiara Di Maio, Francesca Ceccherini‐Silberstein, Valeria Cento et al.|Liver International|2017Cited by 90
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?Velia Chiara Di Maio, L. Lambiase, Valeria Cento et al.|Journal of Hepatology|2017Cited by 31
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experienceAntonio Ascione, Vincenzo Messina, Cleo Study Group et al.|World Journal of Hepatology|2016Cited by 9
Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapiesVelia Chiara Di Maio, M. Paoloni, Valeria Cento et al.|Journal of Hepatology|2017Cited by 2